BACKGROUND: There remains no FDA approved medication for the treatment of cocaine dependence. Preclinical studies and early pilot clinical investigations have suggested that N-acetylcysteine (NAC) may be useful in the treatment of the disorder. OBJECTIVE: The present report assessed the efficacy of NAC in the treatment of cocaine dependence. METHODS:Cocaine-dependent volunteers (n = 111) were randomized to receive daily doses of 1,200 mg of NAC, 2,400 mg of NAC, or placebo. Participants were followed for 8 weeks (up to three visits weekly). At each of these visits, urine samples were collected, along with self-reports of cocaine use. Urine samples were assessed for quantitative levels of benzoylecognine (ie, cocaine metabolite). RESULTS: Overall, the primary results for the clinical trial were negative. However, when considering only subjects who entered the trial having already achieved abstinence, results favored the 2,400 mg NAC group relative to placebo, with the 2,400 mg group having longer times to relapse and lower craving ratings. CONCLUSION: While the present trial failed to demonstrate that NAC reduces cocaine use in cocaine-dependent individuals actively using, there was some evidence it prevented return to cocaine use in individuals who had already achieved abstinence from cocaine. SCIENTIFIC SIGNIFICANCE: N-acetylcysteine may be useful as a relapse prevention agent in abstinent cocaine-dependent individuals.
RCT Entities:
BACKGROUND: There remains no FDA approved medication for the treatment of cocaine dependence. Preclinical studies and early pilot clinical investigations have suggested that N-acetylcysteine (NAC) may be useful in the treatment of the disorder. OBJECTIVE: The present report assessed the efficacy of NAC in the treatment of cocaine dependence. METHODS:Cocaine-dependent volunteers (n = 111) were randomized to receive daily doses of 1,200 mg of NAC, 2,400 mg of NAC, or placebo. Participants were followed for 8 weeks (up to three visits weekly). At each of these visits, urine samples were collected, along with self-reports of cocaine use. Urine samples were assessed for quantitative levels of benzoylecognine (ie, cocaine metabolite). RESULTS: Overall, the primary results for the clinical trial were negative. However, when considering only subjects who entered the trial having already achieved abstinence, results favored the 2,400 mg NAC group relative to placebo, with the 2,400 mg group having longer times to relapse and lower craving ratings. CONCLUSION: While the present trial failed to demonstrate that NAC reduces cocaine use in cocaine-dependent individuals actively using, there was some evidence it prevented return to cocaine use in individuals who had already achieved abstinence from cocaine. SCIENTIFIC SIGNIFICANCE: N-acetylcysteine may be useful as a relapse prevention agent in abstinent cocaine-dependent individuals.
Authors: David A Baker; Krista McFarland; Russell W Lake; Hui Shen; Xing-Chun Tang; Shigenobu Toda; Peter W Kalivas Journal: Nat Neurosci Date: 2003-07 Impact factor: 24.884
Authors: Megan M Moran; Krista McFarland; Roberto I Melendez; Peter W Kalivas; Jeremy K Seamans Journal: J Neurosci Date: 2005-07-06 Impact factor: 6.167
Authors: Khaled Moussawi; Wenhua Zhou; Haowei Shen; Carmela M Reichel; Ronald E See; David B Carr; Peter W Kalivas Journal: Proc Natl Acad Sci U S A Date: 2010-12-20 Impact factor: 11.205
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: K M Kampman; J R Volpicelli; D E McGinnis; A I Alterman; R M Weinrieb; L D'Angelo; L E Epperson Journal: Addict Behav Date: 1998 Jul-Aug Impact factor: 3.913
Authors: B Levi Bolin; Joseph L Alcorn; Joshua A Lile; Craig R Rush; Abner O Rayapati; Lon R Hays; William W Stoops Journal: Drug Alcohol Depend Date: 2017-06-29 Impact factor: 4.492
Authors: Erin A McClure; Nathaniel L Baker; Cassandra D Gipson; Matthew J Carpenter; Amanda P Roper; Brett E Froeliger; Peter W Kalivas; Kevin M Gray Journal: Am J Drug Alcohol Abuse Date: 2014-07-25 Impact factor: 3.829
Authors: Ronald Kim; Marian T Sepulveda-Orengo; Kati L Healey; Emily A Williams; Kathryn J Reissner Journal: Neuropharmacology Date: 2017-09-14 Impact factor: 5.250
Authors: Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure; Rachel L Tomko; Vitria Adisetiyo; Kevin M Gray Journal: Addict Behav Date: 2016-08-04 Impact factor: 3.913